Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

It may not be quite time to throw out the psychiatrist’s couch, but Oxford Professor of Psychiatry Andrea Cipriani is hoping his research might transform the traditional approach to mental health treatment.

Professor Andrea Cipriani

Working with his multidisciplinary team at the Oxford Precision Psychiatry Lab, the Italian-born professor is conducting evidence-based research into treatment for depression; if successful, this research could transform the way people with mental health conditions are treated by medical practitioners in the NHS. 

Rather than embarking on long trial-and-error course, Professor Cipriani’s research looks to introduce a more rigorous, reliable approach to find the right treatment for each individual, using a shared decision-making process, which takes into account patients’ personal preferences and values.

The research will encompass information from 40,000 cases of depression from hundreds of randomised trials, as well as real world data about treatment impact on 700,000 NHS patients. The aim is to identify patterns within individual treatment journeys -  such as what has been proven to work or has been better tolerated for people with specific characteristics. In a field where – 'unfairly' – commonly prescribed medications are believed  not to be substantially different, this personalised approach will help clinicians and patients decide together which treatment suits them best, when they agree to start an antidepressant. Results from this research can save time and suffering for the patients, and also money and resources for the NHS, improving outcomes for all parties.

Read the full article on the University of Oxford website

Similar stories

The Nuffield Department of Women's & Reproductive Health's Clinical Research Group recruits its 2,000th participant to the Generation Study

Oxford’s Clinical Research Group (CRG) has reached an important milestone after recruiting its 2,000th participant to the nationwide Generation Study.

Dementias Platform UK (DPUK) blood biomarker project takes next step towards NHS dementia diagnosis

A project involving researchers from the Universities of Oxford and Cambridge, Imperial College London and Dementias Platform UK (DPUK) has been selected for a major UK initiative aimed at improving dementia diagnosis and helping more people access the support and treatment they need sooner.

Robotic hip and knee surgery fails to cut overall risk of repeat surgery

Two major studies from the University of Oxford, Queen Mary University of London and the University of Bristol, have found that robotic-assisted hip and knee replacement does not reduce the overall early risk of repeat surgery compared with conventional surgery.

Oxford medical student takes AI safety message to the Palace of Versailles

Oxford medical student Julian Shellard has presented at an international workshop on the future of Artificial Intelligence (AI) at the Palace of Versailles in Paris, highlighting the important role medical students can play in global conversations on shaping the future of science and medicine.

Everyday DNA damage reveals a hidden weakness in some cancers

Researchers in the Chapman Group at the MRC Weatherall Institute of Molecular Medicine, have discovered why cancer cells lacking a protein called ATM are particularly vulnerable to a class of cancer drugs known as PARP inhibitors, solving a scientific puzzle that has challenged researchers for nearly 20 years.

Dunn School publishes new children’s book to mark centenary

The collaboration with Oxford University Press brings the story of the development of Penicillin to a new audience